Skip to main content
    R

    ResMed Inc (RMD)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $237.95
    -0.24 (-0.10%)

    Market Cap: $33.69B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    ResMed Inc (RMD) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    ResMed (RMD) has a market cap of $33.69B and an enterprise value of $33.09B. Its return on invested capital of 24.25% compares with a 4.43% median across 10 similar companies. Its trailing P/E of 20.6x is below its 10-year median of 30.0x.

    Total Valuation

    Enterprise value is 1.78% below the market cap, as cash exceeds debt.

    Market Cap$33.69B
    Enterprise Value$33.09B
    Latest price (Nov 17, 2026)$237.95

    Key Dates

    The next earnings report is expected on Jan 27, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Nov 12, 2026.

    Next Earnings DateJan 27, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Last Ex-Dividend DateNov 12, 2026
    Next Payment DateDec 17, 2026
    Fiscal Year EndJune

    Share Statistics

    The share count shrank 0.93% a year over 3 years.

    Shares Outstanding142.99M
    Shares Change (YoY)-2.18%
    Share Count Growth (3Y CAGR)-0.93%

    Valuation Ratios

    Sales and book value multiples are 5.9x and 5.7x. Its year-end P/E ranged from 22.4x to 46.3x from 2016 to 2025.

    P/E Ratio20.6x
    Forward P/E19.4x
    P/S Ratio5.9x
    Forward P/S5.8x
    P/B Ratio5.7x
    P/TBV Ratio13.1x
    P/FCF Ratio21.1x
    P/OCF Ratio19.0x
    PEG Ratio2.4

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 15.3x EBITDA and 20.8x free cash flow.

    EV / Earnings20.8x
    EV / Sales5.8x
    EV / EBITDA15.3x
    EV / FCF20.8x

    Price Statistics

    The stock is down 2.14% over 52 weeks and trades 2.52% above its 50-day average.

    Beta (1Y)0.49
    52-Week Change-2.14%
    1-Month Change-0.48%
    3-Month Change+3.75%
    6-Month Change+14.85%
    5-Year Change-12.54%
    10-Year Change+284.71%
    Total Return (1Y)-1.10%
    Total Return (3Y CAGR)+17.82%
    Total Return (5Y CAGR)-1.18%
    Return vs SPY (1Y)-14.39%
    Max Drawdown (1Y)-33.58%
    Max Drawdown (3Y)-37.45%
    Sharpe Ratio (1Y)-0.09
    Correlation with SPY (1Y)0.22
    50-Day Average$232.10
    200-Day Average$222.83
    52-Week Range$179.26 to $274.65
    RSI (14 Days)51.2
    Average Volume (20 Days)1.44M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.65x current liabilities, and total debt is 0.07x shareholder equity.

    Current Ratio2.65x
    Quick Ratio1.88x
    Debt / Equity0.07x
    Debt / EBITDA0.19x
    Debt / FCF0.25x

    Returns and Efficiency

    Return on invested capital is 24.25% over the last 12 months, against a 5-year average of 19.36%.

    Return on Equity (ROE)26.79%
    Return on Assets (ROA)19.40%
    Return on Invested Capital (ROIC)24.25%
    ROE (5Y Average)22.50%
    ROA (5Y Average)15.51%
    ROIC (5Y Average)19.36%
    Asset Turnover0.69x
    Inventory Turnover2.27x
    Receivables Turnover5.71x
    Cash Conversion Cycle173 days

    Taxes

    Income tax took 20.81% of pretax income over the last 12 months.

    Income Tax (TTM)$418.61M
    Effective Tax Rate20.81%

    Scores

    RMD has an Altman Z-Score of 12.11, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score12.11
    Altman Z ZoneSafe
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $5.73B over the last 12 months is up 9.04% from the 12 months before.

    Revenue$5.73B
    Revenue Growth (YoY)+9.04%
    Gross Profit$3.50B
    Operating Income$1.89B
    Pretax Income$2.01B
    Net Income$1.59B
    EBITDA$2.19B
    Reported EPS (TTM)$11.53

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 72.47% of the $8.21B in total assets.

    Cash and Equivalents$1.01B
    Total Debt$409.60M
    Net Cash$601.14M
    Net Cash Per Share$4.20
    Working Capital$2.18B
    Shareholder Equity$5.95B
    Book Value Per Share$41.60
    Tangible Book Value$2.60B
    Tangible Book Per Share$18.16
    Total Assets$8.21B
    Total Liabilities$2.26B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $162.06M of capital spending, operating cash flow left $1.61B of free cash flow.

    Operating Cash Flow$1.77B
    Capital Expenditures$162.06M
    Free Cash Flow$1.61B
    FCF Per Share$11.44
    Depreciation and Amortization$238.31M
    Dividends Paid$356.87M
    Share Repurchases$1.49B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 33.02%, against a 5-year average of 29.81%.

    Gross Margin61.08%
    Operating Margin33.02%
    Pretax Margin35.09%
    Net Margin27.79%
    EBITDA Margin38.12%
    FCF Margin28.06%
    Gross Margin (5Y Average)57.89%
    Operating Margin (5Y Average)29.81%
    Net Margin (5Y Average)23.80%

    Growth

    Revenue grew 10.21% a year over 3 years, and EPS 20.09% a year.

    Revenue Growth (3Y CAGR)+10.21%
    Revenue Growth (5Y CAGR)+12.08%
    EPS Growth (3Y CAGR)+20.09%
    EPS Growth (5Y CAGR)+15.95%
    FCF Growth (3Y CAGR)+42.20%
    FCF Growth (5Y CAGR)+21.07%
    Operating Income Growth (3Y CAGR)+18.57%

    Revenue and profit by year

    Dividends and Yields

    RMD pays out 20.35% of earnings as dividends.

    Dividend Per Share (Annual)$2.64
    Dividend Yield1.11%
    Payment ScheduleQuarterly
    Dividend Growth (3Y CAGR)+9.53%
    Dividend Growth (5Y CAGR)+7.70%
    Payout Ratio20.35%
    FCF Payout Ratio22.18%
    Earnings Yield4.85%
    FCF Yield4.73%
    Buyback Yield4.16%
    Shareholder Yield5.21%

    Full dividend history

    Stock Splits

    The last split was a 2-for-1 forward split on Aug 31, 2010.

    Last Split DateAug 31, 2010
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 11 similar companies, RMD has the 8th highest P/E.

    P/E Ratio20.6x vs 20.7x median
    P/S Ratio5.9x vs 3.0x median
    ROIC24.25% vs 4.43% median
    Revenue Growth (Trailing 4 Quarters, YoY)+9.04% vs +10.72% median
    Dividend Yield1.11% vs 0.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 4.77% and EPS growth at 8.82% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+4.77%
    EPS Growth Forecast (2Y CAGR)+8.82%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RMD

    What is RMD's market cap?

    ResMed has a market cap of $33.69B. Its enterprise value, which adds debt and subtracts cash, is $33.09B.

    What is RMD's P/E ratio?

    ResMed has a trailing P/E ratio of 20.6x and a forward P/E of 19.4x.

    How many shares of RMD are outstanding?

    ResMed has 142.99M shares outstanding. The count is down 2.18% from a year earlier.

    Does RMD pay a dividend?

    Yes. ResMed pays $2.64 a share a year, a dividend yield of 1.11%.

    How much debt does RMD have?

    ResMed has $409.60M of total debt and $1.01B of cash and equivalents, a net cash position of $601.14M.